Immunotherapy in triple-negative breast cancer: A literature review and new advances

被引：27

作者：

Valencia, Guillermo Arturo ^{[1
]}

Rioja, Patricia ^{[1
]}

Morante, Zaida ^{[1
]}

Ruiz, Rossana ^{[1
]}

Fuentes, Hugo ^{[1
]}

Castaneda, Carlos A. ^{[1
]}

Vidaurre, Tatiana ^{[1
]}

Neciosup, Silvia ^{[1
]}

Gomez, Henry L. ^{[1
]}

机构：

[1] Inst Nacl Enfermedades Neoplasicas, Dept Med Oncol, Angamos Este Ave 2520, Lima 15036, Peru

来源：

WORLD JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 13卷 / 03期

关键词：

Triple-negative breast cancer; Early disease; Immunotherapy; Biomarkers; Metastatic disease; TUMOR-INFILTRATING LYMPHOCYTES; PROGNOSTIC ROLE; DOUBLE-BLIND; EXPRESSION; SUBTYPES; PD-L1; PEMBROLIZUMAB; ATEZOLIZUMAB; CHEMOTHERAPY; PACLITAXEL;

D O I：

10.5306/wjco.v13.i3.219

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple-negative breast cancer (TNBC) is a highly complex, heterogeneous disease and historically has limited treatment options. It has a high probability of disease recurrence and rapid disease progression despite adequate systemic treatment. Immunotherapy has emerged as an important alternative in the management of this malignancy, showing an impact on progression-free survival and overall survival in selected populations. In this review we focused on immunotherapy and its current relevance in the management of TNBC, including various scenarios (metastatic and early -neoadjuvant, adjuvant-), new advances in this subtype and the research of potential predictive biomarkers of response to treatment.

引用

页码：219 / 236

页数：18

共 66 条

[1] Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. [J].

Adams, Sylvia ;

Schmid, Peter ;

Rugo, Hope S. ;

Winer, Eric P. ;

Loirat, Delphine ;

Awada, Ahmad ;

Cescon, David W. ;

Iwata, Hiroji ;

Campone, Mario ;

Nanda, Rita ;

Hui, Rina ;

Curigliano, Giuseppe ;

Toppmeyer, Deborah ;

O'Shaughnessy, Joyce ;

Loi, Sherene ;

Paluch-Shimon, Shani ;

Card, Deborah ;

Zhao, Jing ;

Karantza, Vassiliki ;

Cortes, Javier .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[2] St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment [J].

Balic, Marija ;

Thomssen, Christoph ;

Wuerstlein, Rachel ;

Gnant, Michael ;

Harbeck, Nadia .

BREAST CARE, 2019, 14 (02) :103-110

[3] Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Mayer, I. A. ;

Vahdat, L. T. ;

Tolaney, S. M. ;

Isakoff, S. J. ;

Diamond, J. R. ;

O'Shaughnessy, J. ;

Moroose, R. L. ;

Santin, A. D. ;

Abramson, V. G. ;

Shah, N. C. ;

Rugo, H. S. ;

Goldenberg, D. M. ;

Sweidan, A. M. ;

Iannone, R. ;

Washkowitz, S. ;

Sharkey, R. M. ;

Wegener, W. A. ;

Kalinsky, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08) :741-751

[4] Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome [J].

Beckers, Rhiannon K. ;

Selinger, Christina I. ;

Vilain, Ricardo ;

Madore, Jason ;

Wilmott, James S. ;

Harvey, Kate ;

Holliday, Anne ;

Cooper, Caroline L. ;

Robbins, Elizabeth ;

Gillett, David ;

Kennedy, Catherine W. ;

Gluch, Laurence ;

Carmalt, Hugh ;

Mak, Cindy ;

Warrier, Sanjay ;

Gee, Harriet E. ;

Chan, Charles ;

McLean, Anna ;

Walker, Emily ;

McNeil, Catriona M. ;

Beith, Jane M. ;

Swarbrick, Alexander ;

Scolyer, Richard A. ;

O'Toole, Sandra A. .

HISTOPATHOLOGY, 2016, 69 (01) :25-34

[5] How I treat metastatic triple-negative breast cancer [J].

Caparica, Rafael ;

Lambertini, Matteo ;

de Azambuja, Evandro .

ESMO OPEN, 2019, 4

[6] Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting [J].

Carbognin, Luisa ;

Pilotto, Sara ;

Nortilli, Rolando ;

Brunelli, Matteo ;

Nottegar, Alessia ;

Sperduti, Isabella ;

Giannarelli, Diana ;

Bria, Emilio ;

Tortora, Giampaolo .

ONCOLOGIST, 2016, 21 (03) :283-291

[7] 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [J].

Cardoso, F. ;

Paluch-Shimon, S. ;

Senkus, E. ;

Curigliano, G. ;

Aapro, M. S. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Bhattacharyya, G. S. ;

Biganzoli, L. ;

Boyle, F. ;

Cardoso, M-J ;

Carey, L. A. ;

Cortes, J. ;

El Saghir, N. S. ;

Elzayat, M. ;

Eniu, A. ;

Fallowfield, L. ;

Francis, P. A. ;

Gelmon, K. ;

Gligorov, J. ;

Haidinger, R. ;

Harbeck, N. ;

Hu, X. ;

Kaufman, B. ;

Kaur, R. ;

Kiely, B. E. ;

Kim, S-B ;

Lin, N. U. ;

Mertz, S. A. ;

Neciosup, S. ;

Offersen, B., V ;

Ohno, S. ;

Pagani, O. ;

Prat, A. ;

Penault-Llorca, F. ;

Rugo, H. S. ;

Sledge, G. W. ;

Thomssen, C. ;

Vorobiof, D. A. ;

Wiseman, T. ;

Xu, B. ;

Norton, L. ;

Costa, A. ;

Winer, E. P. .

ANNALS OF ONCOLOGY, 2020, 31 (12) :1623-1649

[8]

ClinicalTrialsgov, STUDY COMPARING ATEZ

[9] KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC [J].

Cortes, J. ;

Cescon, D. W. ;

Rugo, H. S. ;

Im, S-A. ;

Yusof, M. Md ;

Gallardo, C. ;

Lipatov, O. ;

Barrios, C. H. ;

Perez-Garcia, J. ;

Iwata, H. ;

Masuda, N. ;

Otero, M. Torregroza ;

Gokmen, E. ;

Loi, S. ;

Guo, Z. ;

Zhou, X. ;

Karantza, V. ;

Pan, W. ;

Schmid, P. .

ANNALS OF ONCOLOGY, 2021, 32 :S1289-S1290

[10]

Cortes J., 2019, Ann Oncol, V30, pv851, DOI DOI 10.1093/ANN0NC/MDZ394

← 1 2 3 4 5 6 7 →